Melanoma tumors harbor driver mutations mainly in two genes, BRAF and NRAS. Whereas many inhibitors directed to mutated BRAF and MEK have been synthesized and used for treatment, more specific and efficient NRAS-directed agents are still lacking. Here, BRAF is linked to melanoma.